175 related articles for article (PubMed ID: 33549503)
21. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
23. The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis.
Alabi FO; Alkhateeb HA; Zibanayi MT; Garces J; DeBarros KM; Barletti PSB; Garcia K; James RK
BMC Pulm Med; 2023 Jun; 23(1):216. PubMed ID: 37337205
[TBL] [Abstract][Full Text] [Related]
24. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis.
Fitch K; Iwasaki K; Pyenson B; Plauschinat C; Zhang J
Curr Med Res Opin; 2011 Jul; 27(7):1425-9. PubMed ID: 21599554
[TBL] [Abstract][Full Text] [Related]
25. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
26. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
27. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).
Cecere LM; Slatore CG; Uman JE; Evans LE; Udris EM; Bryson CL; Au DH
COPD; 2012 Jun; 9(3):251-8. PubMed ID: 22497533
[TBL] [Abstract][Full Text] [Related]
28. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
Wurst KE; Shukla A; Muellerova H; Davis KJ
COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
[TBL] [Abstract][Full Text] [Related]
29. Development of MDS-Based Predication Model for COPD Severity in Nursing Home Residents.
Blaylock B; Niu X; Davidson HE; Gravenstein S; DePue R; Williams GR; Steinberg KE
Ann Pharmacother; 2022 Aug; 56(8):878-887. PubMed ID: 34963317
[TBL] [Abstract][Full Text] [Related]
30. Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey.
Sen E; Guclu SZ; Kibar I; Ocal U; Yilmaz V; Celik O; Cimen F; Topcu F; Orhun M; Tereci H; Konya A; Ar I; Saryal S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2657-63. PubMed ID: 26715844
[TBL] [Abstract][Full Text] [Related]
31. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
[TBL] [Abstract][Full Text] [Related]
32. Common lung conditions: chronic obstructive pulmonary disease.
Delzell JE
FP Essent; 2013 Jun; 409():23-31. PubMed ID: 23767419
[TBL] [Abstract][Full Text] [Related]
33. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
Wilkie M; Finch S; Schembri S
COPD; 2015; 12(5):582-90. PubMed ID: 25774769
[TBL] [Abstract][Full Text] [Related]
34. Comorbid Anxiety and Depression, Though Underdiagnosed, Are Not Associated with High Rates of Low-Value Care in Patients with Chronic Obstructive Pulmonary Disease.
Griffith MF; Chen HP; Bekelman DB; Feemster LC; Spece LJ; Donovan LM; Au DH; Carey EP
Ann Am Thorac Soc; 2021 Mar; 18(3):442-451. PubMed ID: 33306930
[No Abstract] [Full Text] [Related]
35. A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management.
Micheletto C; Braido F; Contoli M; Di Marco F; Santus P
Int J Chron Obstruct Pulmon Dis; 2019; 14():2185-2193. PubMed ID: 31576115
[TBL] [Abstract][Full Text] [Related]
36. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
Ivanov Y; Nikolaev I; Nemeth I
Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
[TBL] [Abstract][Full Text] [Related]
37. Chronic obstructive pulmonary disease--a treatable disease.
Osthoff M; Jenkins C; Leuppi J
Swiss Med Wkly; 2013; 143():w13777. PubMed ID: 23592218
[TBL] [Abstract][Full Text] [Related]
38. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
39. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.
Magnussen H; Watz H; Kirsten A; Decramer M; Dahl R; Calverley PM; Towse L; Finnigan H; Tetzlaff K; Disse B
Respir Med; 2014 Apr; 108(4):593-9. PubMed ID: 24477080
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
